Medical Bed
We are Hospital Electric From China Manufacturer Medical Bed, also known as Hospital Bed Home Care, Hospital Equipment, Nursing Bed, etc., is a hospital bed used by patients when they are hospitalized in the hospital.
There are many classifications of medical beds, and the specific classification methods are as follows: According to the material, it can be divided into ABS medical beds, all stainless steel medical beds, semi-stainless steel medical beds, all steel sprayed medical beds, etc.
According to the function, it can be divided into electric medical beds and manual medical beds. Among them, electric medical beds can be divided into five-function electric medical beds and three-function electric medical beds. Manual medical beds can be divided into double-shake medical beds and single-shake medical beds. Medical beds, flat medical beds.
According to whether it can be moved, it can be divided into a wheeled medical bed and a right-angle medical bed. Among them, electric medical beds are generally movable with wheels.
Medical Bed,Electric Wooden Bed,Medical Bed Hospital Electric,Hospital Bed Home Care Haloxylon Ammodendron Medical Equipment Co., Ltd. , https://www.halowheelchair.com
Utilizing Transgenic Virus to Treat Rat Brain Tumors
American scientists said on the 8th that they used a genetically modified virus to treat mice that had been transplanted with human malignant brain tumors to achieve results, significantly prolonging the life span of experimental mice without harming healthy cells. According to Xinhua News Agency, Los Angeles, April 8, the research team headed by Professor Antonio Chiogka of the Ohio State University published a paper in the latest issue of Cancer Research. He believed that genetically modified virus may be the most effective and most effective treatment for malignant brain tumors in the future. Safe treatment. The brain tumors treated by the researchers are malignant gliomas. The mortality rate is generally 100%, and most patients die within one year after diagnosis. Surgical, radiotherapy, and chemotherapy methods have no obvious effect on malignant gliomas. . In the last 30 years, the life span after diagnosis of this cancer patient has not been extended. To deal with this tumor cell, the researchers used a genetic oncolytic virus. This oncolytic virus is a type of herpes simplex virus that infects certain cancer cells and reproduces them internally, eventually killing cancer cells. Therefore, its type of transgene has recently been used in experiments for cancer treatment. The researchers found that the genetically modified oncolytic virus in the laboratory lacked some key genes. Although it can accurately identify glioma cells, the rate of reproduction declines dramatically after entering the cells. So they restored a gene called ICP34.5 to an oncolytic virus with some genes removed, making this novel oncolytic virus able to multiply inside cancer cells. The reconstructed ICP34.5 gene has been modified to start only in the presence of nestin. Nestin is usually found in neural stem cells at the embryonic stage, whereas in adults, glioma cells are the only cells that are rich in nestin. In this way, oncolytic viruses only target glioma cells without reaching healthy cells. The researchers first validated the efficacy of oncolytic viruses using laboratory-grown glioma cells. Afterwards, they performed comparative experiments with experimental mice transplanted with human glioma cells. As a result, it was found that if mice were injected with transgenic oncolytic cells 7 days after transplantation, 80% of the experimental mice could survive for more than 90 days, and the untreated mice could only survive for 21 days, and the injection did not contain ICP34.5 gene. In the control group of oncolytic virus mice, only 20% survived for more than 90 days. In clinical treatment, most patients are actually diagnosed and treated late in the disease. In response to this situation, the researchers also performed validation on transplanted glioma cells for 19 days. They found that 20% of the mice injected with the transgenic oncolytic virus survived for more than 24 days, while the experimental mice injected with the control virus all died within 21 days. Chioka said that if human patients can prolong the lifespan after diagnosis in the same proportion, the treatment of malignant gliomas is a great progress, but the path of viral therapy to clinical trials is still very long.